[{"address1": "117 Kendrick Street", "address2": "Suite 500", "city": "Needham", "state": "MA", "zip": "02494", "country": "United States", "phone": "781 292 4200", "website": "https://www.verastem.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.", "fullTimeEmployees": 73, "companyOfficers": [{"maxAge": 1, "name": "Mr. Daniel W. Paterson", "age": 62, "title": "President, CEO & Director", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 897590, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Calkins", "age": 35, "title": "CFO and Principal Accounting & Financial Officer", "yearBorn": 1988, "fiscalYear": 2023, "totalPay": 401833, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard H. Aldrich M.B.A.", "age": 69, "title": "Founder and Consultant", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 38387, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert A. Weinberg Ph.D.", "title": "Co-Founder & Chair of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Piyush B. Gupta Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michelle  Dipp M.D., Ph.D.", "age": 47, "title": "Co-Founder", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jonathan  Pachter Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 238176, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nate  Sanburn", "title": "Senior Vice President of Corporate Development & External Engagement", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cathy  Carew", "title": "Chief Organizational Effectiveness Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Crowther", "title": "Chief Commercial & Business Strategy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 9, "compensationRisk": 6, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.59, "open": 2.72, "dayLow": 2.7002, "dayHigh": 2.9, "regularMarketPreviousClose": 3.59, "regularMarketOpen": 2.72, "regularMarketDayLow": 2.7002, "regularMarketDayHigh": 2.9, "beta": 0.187, "forwardPE": -0.8819876, "volume": 567310, "regularMarketVolume": 567310, "averageVolume": 915103, "averageVolume10days": 533900, "averageDailyVolume10Day": 533900, "bid": 2.82, "ask": 2.87, "bidSize": 100, "askSize": 100, "marketCap": 71924704, "fiftyTwoWeekLow": 2.6, "fiftyTwoWeekHigh": 14.22, "fiftyDayAverage": 5.122, "twoHundredDayAverage": 8.5193, "currency": "USD", "enterpriseValue": 54437728, "floatShares": 13532708, "sharesOutstanding": 25325600, "sharesShort": 1278627, "sharesShortPriorMonth": 2384525, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.0505, "heldPercentInsiders": 0.0075700004, "heldPercentInstitutions": 0.66931, "shortRatio": 1.19, "shortPercentOfFloat": 0.0508, "impliedSharesOutstanding": 25325600, "bookValue": 0.99, "priceToBook": 2.8686867, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -105516000, "trailingEps": -4.28, "forwardEps": -3.22, "pegRatio": -0.5, "lastSplitFactor": "1:12", "lastSplitDate": 1685577600, "enterpriseToEbitda": -0.54, "52WeekChange": -0.624477, "SandP52WeekChange": 0.21656322, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "VSTM", "underlyingSymbol": "VSTM", "shortName": "Verastem, Inc.", "longName": "Verastem, Inc.", "firstTradeDateEpochUtc": 1327674600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "beed18bc-04ae-39af-bc79-04e660295dcc", "messageBoardId": "finmb_115881768", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.84, "targetHighPrice": 36.0, "targetLowPrice": 16.0, "targetMeanPrice": 22.21, "targetMedianPrice": 20.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 110125000, "totalCashPerShare": 4.348, "ebitda": -100761000, "totalDebt": 52485000, "quickRatio": 4.133, "currentRatio": 4.403, "debtToEquity": 113.552, "returnOnAssets": -0.51550996, "returnOnEquity": -2.10181, "freeCashflow": -55035876, "operatingCashflow": -94481000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-24"}]